In the aforementioned study, PAMAM-g-HNTs were used to deliver siRNA against a vascular endothelial growth factor (VEGF) to breast cancer cell lines (MCF-7 and 4T1) and a 4T1-bearing mice model. Here, VEGFA is linked to breast carcinoma.